The pattern of antiviral protein expression induced by interferon λ1 in peripheral blood mononuclear cells of patients with chronic hepatitis C virus infection
- 40 Downloads
Interferon lambda was discovered in recent years to be an antiviral agent, and research on different aspects of this antiviral factor in viral infection and investigations of its effectiveness are also progressing. The immunological effects of interferon lambda on different cell populations is not precisely known, which may be due to its use of a heterodimeric receptor consisting of IL-10R2 and IFN-λR1, which are not broadly expressed in all types of cells. In the present study, signaling by interferon lambda and its effect on the expression of hepatitis C virus (HCV) proteins were measured, and the expression pattern of some antiviral proteins and IL-10 levels were investigated in peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from 50 patients with chronic genotype 1a HCV infection and 10 healthy individuals as controls. The PBMCs were treated with various doses of interferon lambda at different times of cultivation. Real-time PCR was used for relative quantification of Mxa, PKR, OAS, ISG15 and HCV core mRNAs. Expression of the NS5A protein was measured by flow cytometry, and IL-10 production was assessed by ELISA. A significant increase in the expression of mRNA encoding antiviral proteins and a decrease in the expression of mRNAs encoding the HCV core protein were observed when cells were treated with interferon lambda in an intermittent manner. The expression of HCV NS5A protein and interleukin 10 levels were also lower than in the control group. It was shown that the maximum antiviral effect of interferon lambda in PBMCs is dependent on the dose and treatment time.
This work was supported by a grant (Med-52/4915) from the Research Deputy of Tarbiat Modares University, Faculty of Medical Sciences, as a part of a PhD thesis, and a research grant from the Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences (95-02-138-28256).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (94/144).
Informed consent was obtained from all individual participants included in the study.
- 2.Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80(9):4501–4509. https://doi.org/10.1128/jvi.80.9.4501-4509.2006 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E (2008) Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 47(5):1446–1452. https://doi.org/10.1002/hep.22184 CrossRefPubMedGoogle Scholar
- 7.Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G, Pierangeli A (2014) Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol 203(3):177–184. https://doi.org/10.1007/s00430-014-0330-9 CrossRefPubMedGoogle Scholar
- 10.Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, Szabo G (2012) Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PloS One 7(10):e44915. https://doi.org/10.1371/journal.pone.0044915 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Duong FHT, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH (2014) IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med 211(5):857–868. https://doi.org/10.1084/jem.20131557 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, Zhao Z, Navarro MB, Kirschman KD, Bykadi S, Jubin RG, Rabin RL (2012) Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 90(8):774–783. https://doi.org/10.1038/icb.2011.109 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59(4):1250–1261. https://doi.org/10.1002/hep.26653 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Chen C-L, Huang JY, Wang C-H, Tahara SM, Zhou L, Kondo Y, Schechter J, Su L, Lai MMC, Wakita T, Cosset F-L, Jung JU, Machida K (2017) Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun 8:13882. https://doi.org/10.1038/ncomms13882 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Kelly A, Robinson MW, Roche G, Biron CA, O’Farrelly C, Ryan EJ (2016) Immune cell profiling of IFN-λ response shows pDCs express highest level of IFN-λR1 and are directly responsive via the JAK-STAT pathway. J Interferon Cytokine Res 36(12):671–680. https://doi.org/10.1089/jir.2015.0169 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S (2010) Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PloS One 5(12):e15200. https://doi.org/10.1371/journal.pone.0015200 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69–77. https://doi.org/10.1038/ni875 CrossRefPubMedGoogle Scholar
- 35.Lind K, Svedin E, Utorova R, Stone VM, Flodstrom-Tullberg M (2014) Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clin Exp Immunol 177(3):687–695. https://doi.org/10.1111/cei.12368 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887–1898. https://doi.org/10.1053/j.gastro.2006.09.052 CrossRefPubMedGoogle Scholar
- 43.Andersen H, Meyer J, Freeman J, Doyle SE, Klucher K, Miller DM, Hausman D, Hillson JL (2013) Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic. J Clin Transl Hepatol 1(2):116–124. https://doi.org/10.14218/JCTH.2013.00014 CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Ann Rev Immunol 32:513–545. https://doi.org/10.1146/annurev-immunol-032713-120231 CrossRefGoogle Scholar
- 51.Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, Gale M Jr (2003) Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77(7):3898–3912. https://doi.org/10.1128/jvi.77.7.3898-3912.2003 CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10(8):702–714. https://doi.org/10.1038/gene.2009.72 CrossRefPubMedGoogle Scholar
- 53.Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute SB, Garrigues U, Doyle S, Donnelly RP, Kotenko SV, Fitzgerald-Bocarsly P (2012) Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol (Baltimore, Md: 1950) 189(6):2735–2745. https://doi.org/10.4049/jimmunol.1102038 CrossRefGoogle Scholar